Due to the restricted expression of CD19 on the surface of mature B cells rather than other hematopoietic or nonhematopoietic organs, it has emerged as a key target for immunotherapy in B cell lymphomas. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.